COVID-19

FDA Surveillance of 4 Adverse Events of Interest & Pfizer/BioNTech Vaccine (July 2021) [PDF - 126 KB]

Guillain-Barré Syndrome & Janssen/Johnson and Johnson COVID-19 Vaccine (July 2021) [PDF - 230 KB]

Tocilizumab EUA (July 2021) [PDF - 738 KB]

Casirivimab and Imdevimab (REGEN-COV) EUA Update (June 2021) [PDF - 728 KB]

NPTC Emerging Treatment Update: Bamlanivumab-Etesevimab Distribution Paused (June 2021) [PDF - 294 KB]

FDA warning: mRNA COVID-19 vaccines & myo- and pericarditis (June 2021) [PDF - 146 KB]

Sotrovimab EUA (June 2021) [PDF - 757 KB]

05-2021 COVID Vaccine and myo_pericarditis (June 2021) [PDF - 106 KB]

Suspected COVID-19 P.1 Variant Resistance to bamlanivimab/etesevimab (May 2021) [PDF - 159 KB]

Amended EUA: Pfizer-BioNTech COVID-19 Vaccine_Use in Adolescents Aged 12-15 years (May 2021) [PDF - 244 KB]

COVID-19 Clinical Update - NPTC Meeting (April 2021) [PDF - 199 KB]

Drug Safety Alert_Johnson & Johnson/Janssen Vaccine Update (April 2021) [PDF - 105 KB]

Revocation of Bamlanivimab monotherapy EUA (April 2021) [PDF - 526 KB]

Johnson & Johnson/Janssen COVID-19 Vaccine (April 2021) [PDF - 143 KB]

Janssen COVID-19 Vaccine EUA (Mar 2021) [PDF - 543 KB]

Bamlanivimab and Etesevimab EUA (Feb 2021) [PDF - 748 KB]

NPTC COVID-19 Emerging Treatments & Vaccine Update (Jan 2021) [PDF - 188 KB]

COVID-19 Vaccine Safety Alert: Anaphylaxis (Jan 2021) [PDF - 356 KB]

Moderna COVID-19 Vaccine EUA (Dec 2020) [PDF - 151 KB]

Pfizer-BioNTech-COVID-19-Vaccine EUA (Dec 2020) [PDF - 276 KB]

CDC "v-safe" Vaccination Health Checker [PDF - 137 KB]

Baricitinib + Remdesivir EUA (Nov 2020) [PDF - 295 KB]

Casirivimab and Imdevimab EUA (Nov 2020) [PDF - 789 KB]

Bamlanivimab EUA (Nov 2020) [PDF - 638 KB]

COVID-19 Vaccines Overview (Nov 2020) [PDF - 145 KB]

Routine Vaccination During COVID-19 (Nov 2020) [PDF - 196 KB]

FDA Approval: Remdesivir (Oct 2020) [PDF - 644 KB]

Reporting Adverse Vaccine Events handout (October 2020)

COVID-19 Convalescent Plasma (August 2020)

Remdesivir (Veklury) EUA Update (August 2020)

COVID-19 Impact and Therapies (July 2020)

Dexamethasone for COVID-19 (July 2020)

Revocation of Hydroxychloroquine EUA for COVID-19 (June 2020)

Remdesivir Transfer Guidance (June 2020)

Remdesivir Treatment Priorotization Strategy (June 2020)

Remdesivir (GS-5734) (May 2020)

FDA Drug Safety Communication: Hydroxychloroquine and Heart Rhythm ADEs (April 2020)

Hydroxychloroquine for COVID-19 (March 2020) [PDF - 172 KB]

Unknown Risks with Unapproved COVID-19 Treatments (March 2020)

Vaccinations and COVID-19 (March 2020) [PDF - 101 KB]

Nebulizers and COVID-19 (March 2020) [PDF - 346 KB]

CDC Health Safety Alert: Non-pharmaceutical Chloroquine (March 2020)